Furthermore, brontictuzumab showed a partial response in a double NOTCH1-mutant (HD and PEST domain) ACC patient who received two doses of the antibody therapy during a clinical trial. This evidence concerns the gene NOTCH1 and adrenal cortex carcinoma.